As requested by our invited Chinese pharma and investors, we are now inviting companies that meet their partnering/investment objective to China Focus@BIO Philadelphia.
All applications will be promptly reviewed by the program committee. The selected companies are entitled to a free registration ($995 value) of China Focus event and will provide 8-minute pitch, followed by 1:1 meeting with the guests who express interest in your assets, at our designated VIP partnering areas.
The private pitch is invitation only and the audiences are pharma senior executives and prestigious investors, exclusively. You may find the list as follows and more audiences are joining us.
Featured Guests
Representative:
Lily Zou, CEO, Fosun Pharma US
Larry Cai, Executive Director, Business Development
Representative:
Cynthia Cai, Senior Advisor
Representatives:
Jenny J. Wang, Director Oncology External Innovation, Global Business Development & Licensing
Julie Carnis, Associate Director China & EM
Luye Pharma: Luye pharma is an international pharmaceutical company dedicated to the R$D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of 40 drug candidates in China and more than 10 drug candidates overseas. The company currently has a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. and Europe. Luye Pharma has reached a high level international standard in advanced drug delivery technologies such as microspheres, liposomes and transdermal drug delivery systems. The company is forward looking, with strategic development of innovative new compounds and antibodies, gene & cell therapies and smart formulations.
Representative:
Herwig Janssen, VP, Licensing & Acquisitions Emerging Markets
FC Capital: FC Capital is a cross-border VC/PE fund specialized in healthcare and life science investments. The team operates from its headquarters in Shanghai with additional offices in Taipei and Boston. FC seeks to invest in early stage assets in biopharmaceuticals, medical devices, and healthtech. Current portfolio companies spread across China, Europe, and the United States.
Representative:
Shaoyu Chang, Vice President
Representative:
Herwig Janssen, VP, Licensing & Acquisitions Emerging Markets
Representatives:
Jianying Shi, Vice President
Xuan Peng, Director
Share Capital: Established in Shenzhen in 2007, is the earliest limited partnership professional venture capital institution in China. In the focus area, Share Capital deploys more entrepreneurial projects in the early and mid-stage, and then extend investment in companies with outstanding value to improve the overall return of the fund. Among them, the investment scope of Share Capital in the field of healthcare covers new drug research and development, biotechnology, innovative medical devices, medical and health services and other sub-areas, and formed a new drug research and development, biotechnology as a prominent feature of the investment portfolio.
Representative:
Tom Du, Medical Partner
Representative:
Hongjian Zhang, Managing Director